

Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies

M. Hide, P. Staubach, A. Khemis, V. Jain, W. Huiping, S. Gogate, E.D. Martzloff, S. Haemmerle, C.E. Ortmann, N.C-Rothe, M. Lebwohl

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the abstract after 13 June 2025, once it is available at the congress website